KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) EBITDA (2017 - 2025)

Biomarin Pharmaceutical's EBITDA history spans 16 years, with the latest figure at -$44.6 million for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 127.64% year-over-year to -$44.6 million, compared with a TTM value of $255.3 million through Dec 2025, down 48.61%, and an annual FY2025 reading of $409.5 million, down 15.43% over the prior year.
  • EBITDA for Q4 2025 was -$44.6 million at Biomarin Pharmaceutical, down from -$20.1 million in the prior quarter.
  • The five-year high for EBITDA was $176.8 million in Q2 2025, with the low at -$65.9 million in Q4 2021.
  • Average EBITDA over 5 years is $51.8 million, with a median of $45.5 million recorded in 2022.
  • Year-over-year, EBITDA surged 1060.04% in 2023 and then plummeted 127.64% in 2025.
  • Tracing BMRN's EBITDA over 5 years: stood at -$65.9 million in 2021, then soared by 80.13% to -$13.1 million in 2022, then skyrocketed by 308.43% to $27.3 million in 2023, then skyrocketed by 491.69% to $161.4 million in 2024, then tumbled by 127.64% to -$44.6 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's EBITDA are -$44.6 million (Q4 2025), -$20.1 million (Q3 2025), and $176.8 million (Q2 2025).